Allergan, Inc.

Mayssa Attar

Rhett M Schiffman

Richard S Graham

Michael E Garst

Ken Chow

Liming Wang

Santosh C Sinha

Chin-Ming Chang

Chetan Pujara

Anuradha V Gore

John T Trogden

Adnan K Salameh

Jaya Giyanani

Devin F Welty

Eldon Q Farnes

Brandon D Swift

Andrea S Kim

Ronald Bradford

Eldon Quinn Farnes

Wendy M Blanda

Walter L Tien

Aileen Morgan

David A Hollander

Linda Villanueva

David Hollander

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.

Non-irritating testosterone emulsions

Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.

Cyclosporin compositions

The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug.

Antibiotic conjugates directly linked with steroid drugs

The present invention describes Cyclosporine A/steroid hybrid analogs. These single drug entities are formed by connecting a steroid with Cyclosporine A. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs.

Cyclosporine A steroid conjugates

The present invention provides an aqueous ophthalmic solution with an effective amount of ketorolac and carboxymethyl cellulose in an aqueous solution which provides increased visual acuity and wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Ketorolac tromethamine compositions for treating or preventing ocular pain

Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.

Sustained action formulation of cyclosporin form 2

The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Ketorolac tromethamine compositions for treating ocular pain

Growing community of inventors

Placentia, CA, United States of America

Mayssa Attar